Medical Bulletin 23/October/2021

Published On 2021-10-23 12:15 GMT   |   Update On 2021-10-23 12:15 GMT
Advertisement

Here are Top Medical stories of the day

A combination pill approved for severe acute pain in adults

The US Food and Drug Administration (FDA) has approved Seglentis a combination of celecoxib and tramadol hydrochloride for severe acute pain in adults, especially when alternative treatments fail to provide adequate pain relief.

It is an innovative first-in-class product comprised of a co-crystal form of celecoxib an anti-inflammatory drug and tramadol ,an analgesic for the treatment of acute pain in adults.

Advertisement

For more details, check out the full story on the link below:

FDA Approves Combination Pill For Severe Acute Pain In Adults


Regular Millet consumption may improve iron deficiency Anemia, finds study

The prevalence of iron deficiency anemia is highest among low and middle-income countries where Millets, including sorghum, rich in iron are a traditional staple diet. A wide variation in the iron composition of millets has been reported, which needs to be understood in consonance with its bioavailability and roles in reducing anemia.

Regular consumption of millets can improve hemoglobin and serum ferritin levels to reduce iron deficiency anemia, finds a new study.

For more details, check out the full story on the link below:

Regular Millet Consumption May Improve Iron Deficiency Anemia, Finds Study


Novel stem cell-derived therapy for type 1 diabetes shows promising results

A stem cell-derived potential therapy VX-880 for treating Type 1 diabetes has resulted in a 91% decrease in daily insulin doses in first patient, according to a recent press release.

Vertex Pharmaceuticals Incorporated has shared results of Phase 1/2 of its clinical trial in which after only 90 days of its ongoing investigational study, the patient's insulin needs were reduced from 34 daily units down to 3 daily units.

For more details, check out the full story on the link below:

Novel Stem Cell-Derived Therapy For Type 1 Diabetes Shows Promising Results


Menstrual cycle length during menopause transition may predict risk of future atherosclerosis

Menstrual cycle length has been associated with different chronic conditions, including breast cancer, osteoporosis, and cardiovascular disease.

Changes in cycle length specifically during the menopause transition may also predict a woman's risk of developing atherosclerosis after menopause, finds a new study.

For more details, check out the full story on the link below:

Menstrual Cycle Length During Menopause Transition May Predict Risk Of Future Atherosclerosis


Case of Acute Intermittent Porphyria Presents As Posterior Reversible Encephalopathy Syndrome- A report
Acute intermittent porphyria (AIP) is an autosomal dominant inborn error caused due to inherited deficiency of porphobilinogen (PBG) deaminase leading to increased levels of aminolevulinic acid and PBG.
The most common presentation is an attack of severe abdominal pain without peritoneal signs, often accompanied by nausea, vomiting,tachycardia, hypertension, anxiety, and agitation. AIP is rarely associated with posterior reversible encephalopathy syndrome (PRES) and this association is important because drugs used in the management of seizures may worsen an attack of AIP.

For more details, check out the full story on the link below:



Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News